만성 특발성 두드러기 치료 시장 보고서(2026년)

Chronic idiopathic urticaria treatment refers to the range of medical approaches used to manage persistent hives with no identifiable cause, focusing on relieving itching, swelling, and recurrent flare-ups while enhancing patient quality of life through effective symptom control. Management generally follows a stepwise strategy, beginning with non-sedating antihistamines, followed by increased dosing, additional biologic therapies, immunosuppressive agents, or short-term corticosteroid use in patients with moderate to severe or resistant symptoms.

The primary types of chronic idiopathic urticaria treatments include tablets, capsules, creams, lotions, and injections. Tablets are oral solid dosage forms used to alleviate symptoms associated with chronic urticaria. These treatments fall under drug classes such as antihistamines, corticosteroids, leukotriene receptor antagonists, immunosuppressants, biologic therapies, and other pharmaceutical classes. They are administered and distributed through oral, injectable, and topical routes via hospital pharmacies, retail pharmacies, and online pharmacies.

Tariffs are impacting the chronic idiopathic urticaria treatment market by increasing costs of imported biologic drugs, injectable delivery devices, pharmaceutical excipients, and specialized packaging materials. Hospitals and specialty clinics in North America and Europe are most affected due to reliance on imported biologics, while Asia-Pacific faces pricing pressure on advanced therapy imports. These tariffs are increasing treatment costs and influencing reimbursement dynamics. However, they are also supporting local biologic manufacturing, regional formulation facilities, and long-term investment in domestic immunology drug development.

The chronic idiopathic urticaria treatment market research report is one of a series of new reports from The Business Research Company that provides chronic idiopathic urticaria treatment market statistics, including chronic idiopathic urticaria treatment industry global market size, regional shares, competitors with a chronic idiopathic urticaria treatment market share, detailed chronic idiopathic urticaria treatment market segments, market trends and opportunities, and any further data you may need to thrive in the chronic idiopathic urticaria treatment industry. This chronic idiopathic urticaria treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The chronic idiopathic urticaria treatment market size has grown strongly in recent years. It will grow from $7.24 billion in 2025 to $7.89 billion in 2026 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to increasing diagnosis of chronic urticaria, availability of second-line antihistamine therapies, adoption of stepwise treatment protocols, expansion of allergy specialty clinics, growing use of immunomodulatory drugs.

The chronic idiopathic urticaria treatment market size is expected to see strong growth in the next few years. It will grow to $11.23 billion in 2030 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to increasing demand for biologic treatment options, rising focus on personalized immunology care, expansion of digital disease management tools, growing investment in novel urticaria therapies, increasing patient awareness and treatment adherence. Major trends in the forecast period include increasing adoption of biologic therapies for refractory patients, growing use of personalized treatment pathways, rising integration of digital symptom monitoring tools, expansion of injectable treatment options, enhanced focus on long-term disease control.

The growing focus on biologic therapies is projected to strengthen the expansion of the chronic idiopathic urticaria treatment market in the coming years. Biologics are medical treatments developed from living organisms or their components that target specific immune system pathways to manage diseases. Interest in biologics is increasing due to advances in biotechnology and immunology that enable the creation of precise and highly effective therapies addressing underlying disease mechanisms rather than only symptoms. Biologic treatments act on immune pathways and mast cell activity responsible for chronic idiopathic urticaria, transforming treatment approaches and offering longer-lasting symptom relief. For example, in February 2025, according to the World Health Organization, a Switzerland-based intergovernmental organization, the 2023 Essential Medicines List included 81 biologic therapies, accounting for over 15% of all listed medicines. Therefore, the growing focus on biologics is supporting the growth of the chronic idiopathic urticaria treatment market.

Leading companies operating in the chronic idiopathic urticaria treatment market are emphasizing the development of innovative products, including monoclonal antibody therapies, to deliver targeted and long-lasting relief for patients who do not respond adequately to standard treatments. Monoclonal antibody therapies are biologic medications designed to specifically target immune components such as immunoglobulin E (IgE) or other inflammatory mediators responsible for chronic hives, providing more precise treatment compared with traditional antihistamines or corticosteroids. For example, in September 2025, Celltrion Inc., a South Korea-based biopharmaceutical company, launched Omriclo, an omalizumab biosimilar, in Norway. The product contains the same active monoclonal antibody as Xolair, works by neutralizing circulating IgE, and is administered through subcutaneous injection. Its distinguishing features include first-mover presence in Europe, expanded access via local distribution networks, and potential cost reductions for healthcare systems. It is designed for patients with chronic idiopathic urticaria who continue to experience symptoms despite standard therapies, offering improved symptom control, fewer flare-ups, and enhanced quality of life by reducing reliance on long-term antihistamine or corticosteroid use.

In March 2025, Novartis AG, a Switzerland-based pharmaceutical company, acquired global rights to the preclinical drug KRP-M223 from Kyorin Pharmaceutical Co. Ltd. for an upfront payment of $55 million. Through this agreement, Novartis plans to develop, manufacture, and commercialize KRP-M223, an MRGPRX2 antagonist intended to treat chronic spontaneous urticaria and other mast cell-related inflammatory disorders, while Kyorin retains rights to produce and sell the drug in Japan. Kyorin Pharmaceutical Co. Ltd. is a Japan-based pharmaceutical company focused on therapies for chronic idiopathic urticaria.

Major companies operating in the chronic idiopathic urticaria treatment market are F. Hoffmann-La Roche Ltd., Sanofi S.A., Novartis AG., AstraZeneca PLC, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Incyte Corporation, Dr. Reddy's Laboratories Ltd., Celltrion Inc., Yuhan Corporation, Kiniksa Pharmaceuticals Ltd., Celldex Therapeutics Inc., Septerna Therapeutics Inc., Carna Biosciences Inc., United BioPharma Inc., Recludix Pharma Inc., Jasper Therapeutics Inc., Evommune Inc., ARS Pharmaceuticals Inc

North America was the largest region in the chronic idiopathic urticaria treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic idiopathic urticaria treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the chronic idiopathic urticaria treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chronic idiopathic urticaria treatment market includes revenues earned by entities through clinical diagnosis and disease assessment, allergy and trigger evaluation services, personalized treatment planning, antihistamine therapy management, and treatment response assessments. The market value includes the value of related digital tools and devices sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chronic Idiopathic Urticaria Treatment Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses chronic idiopathic urticaria treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for chronic idiopathic urticaria treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The chronic idiopathic urticaria treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Types: Tablets; Capsules; Creams; Lotions; Injections
• 2) By Drug Class: Antihistamines; Corticosteroids; Leukotriene Receptor Antagonists; Immunosuppressants; Biologic Therapies; Other Drug Class
• 3) By Route Of Administration: Oral; Injectable; Topical
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Tablets: Immediate Release Tablets; Extended Release Tablets; Enteric Coated Tablets; Chewable Tablets; Orally Disintegrating Tablets
• 2) By Capsules: Hard Gelatin Capsules; Soft Gelatin Capsules; Sustained Release Capsules; Delayed Release Capsules
• 3) By Creams: Medicated Topical Creams; Anti Inflammatory Creams; Antifungal Creams; Antibacterial Creams; Moisturizing Therapeutic Creams
• 4) By Lotions: Medicated Therapeutic Lotions; Anti Inflammatory Lotions; Antiseptic Lotions; Moisturizing Lotions; Specialty Dermatological Lotions
• 5) By Injections: Intravenous Injections; Intramuscular Injections; Subcutaneous Injections; Pre Filled Syringe Injections; Auto Injector Based Injections
• Companies Mentioned: F. Hoffmann-La Roche Ltd.; Sanofi S.A.; Novartis AG.; AstraZeneca PLC; GlaxoSmithKline plc; Teva Pharmaceutical Industries Ltd.; Regeneron Pharmaceuticals Inc.; Incyte Corporation; Dr. Reddy's Laboratories Ltd.; Celltrion Inc.; Yuhan Corporation; Kiniksa Pharmaceuticals Ltd.; Celldex Therapeutics Inc.; Septerna Therapeutics Inc.; Carna Biosciences Inc.; United BioPharma Inc.; Recludix Pharma Inc.; Jasper Therapeutics Inc.; Evommune Inc.; ARS Pharmaceuticals Inc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Chronic Idiopathic Urticaria Treatment Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Chronic Idiopathic Urticaria Treatment Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Chronic Idiopathic Urticaria Treatment Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Chronic Idiopathic Urticaria Treatment Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Artificial Intelligence & Autonomous Intelligence
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Increasing Adoption Of Biologic Therapies For Refractory Patients
  • 4.2.2 Growing Use Of Personalized Treatment Pathways
  • 4.2.3 Rising Integration Of Digital Symptom Monitoring Tools
  • 4.2.4 Expansion Of Injectable Treatment Options
  • 4.2.5 Enhanced Focus On Long-Term Disease Control

5. Chronic Idiopathic Urticaria Treatment Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Allergy Clinics
• 5.3 Dermatology Clinics
• 5.4 Specialty Pharmacies
• 5.5 Home Healthcare Providers

6. Chronic Idiopathic Urticaria Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Chronic Idiopathic Urticaria Treatment Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Chronic Idiopathic Urticaria Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Chronic Idiopathic Urticaria Treatment Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Chronic Idiopathic Urticaria Treatment Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Chronic Idiopathic Urticaria Treatment Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Chronic Idiopathic Urticaria Treatment Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Chronic Idiopathic Urticaria Treatment Market Segmentation

• 9.1. Global Chronic Idiopathic Urticaria Treatment Market, Segmentation By Types, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Tablets, Capsules, Creams, Lotions, Injections
• 9.2. Global Chronic Idiopathic Urticaria Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Antihistamines, Corticosteroids, Leukotriene Receptor Antagonists, Immunosuppressants, Biologic Therapies, Other Drug Class
• 9.3. Global Chronic Idiopathic Urticaria Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral, Injectable, Topical
• 9.4. Global Chronic Idiopathic Urticaria Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
• 9.5. Global Chronic Idiopathic Urticaria Treatment Market, Sub-Segmentation Of Tablets, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Immediate Release Tablets, Extended Release Tablets, Enteric Coated Tablets, Chewable Tablets, Orally Disintegrating Tablets
• 9.6. Global Chronic Idiopathic Urticaria Treatment Market, Sub-Segmentation Of Capsules, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hard Gelatin Capsules, Soft Gelatin Capsules, Sustained Release Capsules, Delayed Release Capsules
• 9.7. Global Chronic Idiopathic Urticaria Treatment Market, Sub-Segmentation Of Creams, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Medicated Topical Creams, Anti Inflammatory Creams, Antifungal Creams, Antibacterial Creams, Moisturizing Therapeutic Creams
• 9.8. Global Chronic Idiopathic Urticaria Treatment Market, Sub-Segmentation Of Lotions, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Medicated Therapeutic Lotions, Anti Inflammatory Lotions, Antiseptic Lotions, Moisturizing Lotions, Specialty Dermatological Lotions
• 9.9. Global Chronic Idiopathic Urticaria Treatment Market, Sub-Segmentation Of Injections, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Intravenous Injections, Intramuscular Injections, Subcutaneous Injections, Pre Filled Syringe Injections, Auto Injector Based Injections

10. Chronic Idiopathic Urticaria Treatment Market Regional And Country Analysis

• 10.1. Global Chronic Idiopathic Urticaria Treatment Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Chronic Idiopathic Urticaria Treatment Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Chronic Idiopathic Urticaria Treatment Market

• 11.1. Asia-Pacific Chronic Idiopathic Urticaria Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Chronic Idiopathic Urticaria Treatment Market, Segmentation By Types, Segmentation By Drug Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Chronic Idiopathic Urticaria Treatment Market

• 12.1. China Chronic Idiopathic Urticaria Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Chronic Idiopathic Urticaria Treatment Market, Segmentation By Types, Segmentation By Drug Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Chronic Idiopathic Urticaria Treatment Market

• 13.1. India Chronic Idiopathic Urticaria Treatment Market, Segmentation By Types, Segmentation By Drug Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Chronic Idiopathic Urticaria Treatment Market

• 14.1. Japan Chronic Idiopathic Urticaria Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Chronic Idiopathic Urticaria Treatment Market, Segmentation By Types, Segmentation By Drug Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Chronic Idiopathic Urticaria Treatment Market

• 15.1. Australia Chronic Idiopathic Urticaria Treatment Market, Segmentation By Types, Segmentation By Drug Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Chronic Idiopathic Urticaria Treatment Market

• 16.1. Indonesia Chronic Idiopathic Urticaria Treatment Market, Segmentation By Types, Segmentation By Drug Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Chronic Idiopathic Urticaria Treatment Market

• 17.1. South Korea Chronic Idiopathic Urticaria Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Chronic Idiopathic Urticaria Treatment Market, Segmentation By Types, Segmentation By Drug Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Chronic Idiopathic Urticaria Treatment Market

• 18.1. Taiwan Chronic Idiopathic Urticaria Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Chronic Idiopathic Urticaria Treatment Market, Segmentation By Types, Segmentation By Drug Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Chronic Idiopathic Urticaria Treatment Market

• 19.1. South East Asia Chronic Idiopathic Urticaria Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Chronic Idiopathic Urticaria Treatment Market, Segmentation By Types, Segmentation By Drug Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Chronic Idiopathic Urticaria Treatment Market

• 20.1. Western Europe Chronic Idiopathic Urticaria Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Chronic Idiopathic Urticaria Treatment Market, Segmentation By Types, Segmentation By Drug Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Chronic Idiopathic Urticaria Treatment Market

• 21.1. UK Chronic Idiopathic Urticaria Treatment Market, Segmentation By Types, Segmentation By Drug Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Chronic Idiopathic Urticaria Treatment Market

• 22.1. Germany Chronic Idiopathic Urticaria Treatment Market, Segmentation By Types, Segmentation By Drug Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Chronic Idiopathic Urticaria Treatment Market

• 23.1. France Chronic Idiopathic Urticaria Treatment Market, Segmentation By Types, Segmentation By Drug Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Chronic Idiopathic Urticaria Treatment Market

• 24.1. Italy Chronic Idiopathic Urticaria Treatment Market, Segmentation By Types, Segmentation By Drug Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Chronic Idiopathic Urticaria Treatment Market

• 25.1. Spain Chronic Idiopathic Urticaria Treatment Market, Segmentation By Types, Segmentation By Drug Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Chronic Idiopathic Urticaria Treatment Market

• 26.1. Eastern Europe Chronic Idiopathic Urticaria Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Chronic Idiopathic Urticaria Treatment Market, Segmentation By Types, Segmentation By Drug Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Chronic Idiopathic Urticaria Treatment Market

• 27.1. Russia Chronic Idiopathic Urticaria Treatment Market, Segmentation By Types, Segmentation By Drug Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Chronic Idiopathic Urticaria Treatment Market

• 28.1. North America Chronic Idiopathic Urticaria Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Chronic Idiopathic Urticaria Treatment Market, Segmentation By Types, Segmentation By Drug Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Chronic Idiopathic Urticaria Treatment Market

• 29.1. USA Chronic Idiopathic Urticaria Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Chronic Idiopathic Urticaria Treatment Market, Segmentation By Types, Segmentation By Drug Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Chronic Idiopathic Urticaria Treatment Market

• 30.1. Canada Chronic Idiopathic Urticaria Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Chronic Idiopathic Urticaria Treatment Market, Segmentation By Types, Segmentation By Drug Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Chronic Idiopathic Urticaria Treatment Market

• 31.1. South America Chronic Idiopathic Urticaria Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Chronic Idiopathic Urticaria Treatment Market, Segmentation By Types, Segmentation By Drug Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Chronic Idiopathic Urticaria Treatment Market

• 32.1. Brazil Chronic Idiopathic Urticaria Treatment Market, Segmentation By Types, Segmentation By Drug Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Chronic Idiopathic Urticaria Treatment Market

• 33.1. Middle East Chronic Idiopathic Urticaria Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Chronic Idiopathic Urticaria Treatment Market, Segmentation By Types, Segmentation By Drug Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Chronic Idiopathic Urticaria Treatment Market

• 34.1. Africa Chronic Idiopathic Urticaria Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Chronic Idiopathic Urticaria Treatment Market, Segmentation By Types, Segmentation By Drug Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Chronic Idiopathic Urticaria Treatment Market Regulatory and Investment Landscape

36. Chronic Idiopathic Urticaria Treatment Market Competitive Landscape And Company Profiles

• 36.1. Chronic Idiopathic Urticaria Treatment Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Chronic Idiopathic Urticaria Treatment Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Chronic Idiopathic Urticaria Treatment Market Company Profiles
  • 36.3.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Novartis AG. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

37. Chronic Idiopathic Urticaria Treatment Market Other Major And Innovative Companies

• Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Incyte Corporation, Dr. Reddy's Laboratories Ltd., Celltrion Inc., Yuhan Corporation, Kiniksa Pharmaceuticals Ltd., Celldex Therapeutics Inc., Septerna Therapeutics Inc., Carna Biosciences Inc., United BioPharma Inc., Recludix Pharma Inc., Jasper Therapeutics Inc., Evommune Inc., ARS Pharmaceuticals Inc

38. Global Chronic Idiopathic Urticaria Treatment Market Competitive Benchmarking And Dashboard

39. Upcoming Startups in the Market

40. Key Mergers And Acquisitions In The Chronic Idiopathic Urticaria Treatment Market

41. Chronic Idiopathic Urticaria Treatment Market High Potential Countries, Segments and Strategies

• 41.1 Chronic Idiopathic Urticaria Treatment Market In 2030 - Countries Offering Most New Opportunities
• 41.2 Chronic Idiopathic Urticaria Treatment Market In 2030 - Segments Offering Most New Opportunities
• 41.3 Chronic Idiopathic Urticaria Treatment Market In 2030 - Growth Strategies
  • 41.3.1 Market Trend Based Strategies
  • 41.3.2 Competitor Strategies

42. Appendix

• 42.1. Abbreviations
• 42.2. Currencies
• 42.3. Historic And Forecast Inflation Rates
• 42.4. Research Inquiries
• 42.5. The Business Research Company
• 42.6. Copyright And Disclaimer